Hadassah

Hadassah’s Pulmonary Institute: Innovator in Pulmonary Fibrosis Research

Thursday, Dec 15 2011

The Hadassah University Medical Center's Pulmonary Institute is an innovator in laboratory research aimed at reversal of pulmonary fibrosis, the debilitating formation of excess fibrous connective tissue in the lung.

The Institute is a national referral center for pulmonary fibrosis. Its researchers have developed an animal model that has enabled them to test hypotheses concerning how fibrosis progresses at the molecular and cellular level.

"Pulmonary fibrosis is a special interest of mine," relates Prof. Raphael Breuer, head of the Institute and Founder and Director of Hadassah's Laboratory for Lung and Molecular Biology. "Research to better understand the mechanisms of pulmonary fibrosis and to provide the best possible clinical care for patients with this disease has been a primary focus of my professional life over the last 30 years. I think that many scientists and physicians specializing in this field feel that we are beginning to make real headway with this difficult challenge."

Hadassah's researchers investigate the genes, proteins, and other molecules that lead fibroblasts to accumulate uncontrollably in patients with fibrosis. Their close link with physicians in the Pulmonary Unit, as well as leading pharmaceutical companies, facilitates rapid patient access to novel therapies that emerge from their work and other laboratories worldwide.

Among their findings are:

  • During fibrosis, lung myofibroblasts--the cells that create scars in the lung--acquire an immune-privileged cell phenotype, enabling them to escape from immune surveillance. This mechanism parallels the process that enables cancer cells to escape the immune system and accumulate uncontrollably.
  • The Fas molecule--the antigen recognized by antibodies that initiate programmed cell death-- plays an important role in myofibroblast accumulation. Fas ligand (FasL-positive) myofibroblasts actually kill the immune cells that might otherwise prevent their uncontrolled accumulation.
  • Flice-inhibitory protein (FLIP) diverts Fas signaling and induces the Fas molecule to signal myofibroblasts to accumulate rather than to undergo normal programmed cell death.

Currently, Hadassah researchers are focusing on the role of T lymphocyte immune cells. They have found that, in an animal model, when these T lymphocytes are FasL-positive, they induce myofibroblast cell death and enable clearance of lung myofibroblasts during the resolution of lung fibrosis. The scientists are now seeking to more fully elucidate the roles of Fas molecules, FasL, FLIP, and T lymphocytes in allowing myofibroblast accumulation as well as in the resolution of lung fibrosis.

At present, there is no medication that can reverse or significantly slow the process of lung fibrosis. Based on their findings, however, Hadassah's researchers are proposing a new approach to treatment of pulmonary fibrosis: Instead of suppressing the immune system, they propose blocking the capability of fibrotic lung myofibroblasts from evading T cell-induced apoptosis (programmed cell death). This would enable lymphocytes to more effectively stop uncontrolled fibroblast accumulation, known to be the cause of lethal lung fibrosis.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Aug 15 2019

Argentinian Neurosurgeon Shares His Love for Working at Hadassah

Many years ago, neurosurgeon Andrés Vargas, born in Tucumán, Argentina, chose to live in Israel and practice medicine at Hadassah Hospital Ein Kerem.

READ MORE ›
alt_text

Wednesday, Aug 14 2019

A Hadassah Cystic Fibrosis Expert Advises the Panamanian Government

Dr. Malena Cohen, a pediatric pulmonary specialist at the Hadassah Medical Organization, traveled to Panama last week to explore the idea of opening the first cystic fibrosis (CF) center there.

READ MORE ›
alt_text

Tuesday, Aug 13 2019

Alzheimer’s Further Illuminated at Hadassah with New Exclusive Imaging Agent

The Hadassah Medical Organization, through its subsidiary SRY, has contracted to be the sole Israeli agent for General Electric to produce Vizamy, the company’s new radioactive imaging agent to detect, at an early stage, amyloid plaque, which has been linked to the development of Alzheimer’s disease.

READ MORE ›
alt_text

Friday, Aug 2 2019

New Thyroid Eye Disease Clinic at Hadassah Brings Integrated Care to New Mom

Miriam, 34, had just given birth to her third child, and, unlike the joy she felt after her first two births, she felt awful.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More